Non-conventional doses of somatostatin analogs in patients with progressing well differentiated neuroendocrine tumor.
To evaluate antiproliferative activity and safety of non-conventional doses of somatostatin analogs (HD-SSA) in patients with well-differentiated gastro-entero-pancreatic (GEP) neuroendocrine tumors (NET) with radiological disease progression according to RECIST criteria on a previous treatment. A retrospective analysis of prospectively maintained databases from 13 Italian NET-dedicated centers was performed. Main inclusion criteria were: well-differentiated G1 or G2 GEP-NET, treatment with HD-SSA (either with increased administered dose [dose intensity] or reduced administration interval [dose density]), progressive disease on a previous treatment before HD-SSA treatment. Main endpoints were progression-free survival (PFS) and safety. Of 198 patients, 140 matched inclusion criteria and were included in the analysis. Overall, median PFS was 31 months. Use of HD-SSA as second-line treatment was associated with reduced risk for progression or death compared to third or further line treatment (HR: 2.12, p= 0.004). There was no difference in PFS between HD-SSA by increased dose density (N=133, 95%) or intensity (N=7, 5%). Partial response according to RECIST criteria was observed in 12 patients (8.6%) and 106 (75.7%) achieved stable disease. HD-SSA is an active and safe treatment option in patients with progressive well-differentiated GEP-NET. The high rate of objective responses observed deserves prospective validation in ad hoc clinical trials.